N-[[4-(4-PHENYLPIPERAZIN-1-YL)OXAN-4-YL]METHYL]-2-PHENYLSULFANYLPYRIDINE-3-CARBOXAMIDE CAS#: 1428327-31-4

N-[[4-(4-PHENYLPIPERAZIN-1-YL)OXAN-4-YL]METHYL]-2-PHENYLSULFANYLPYRIDINE-3-CARBOXAMIDE

生物活性靶点体外研究体内研究用途与合成方法 MSDS N-[[4-(4-PHENYLPIPERAZIN-1-YL)OXAN-4-YL]METHYL]-2-PHENYLSULFANYLPYRIDINE-3-CARBOXAMIDE价格(试剂级) 上下游产品信息

中文名称	N-[[4-(4-PHENYLPIPERAZIN-1-YL)OXAN-4-YL]METHYL]-2-PHENYLSULFANYLPYRIDINE-3-CARBOXAMIDE
中文同义词	化合物JNJ-47965567;N-((4-(4-苯基哌嗪-1-基)四氢-2H-吡喃-4-基)甲基)-2-(苯硫基)烟酰胺;JNJ 47965567,P2X7拮抗剂
英文名称	N-((4-(4-phenylpiperazin-1-yl)tetrahydro-2H-pyran-4-yl)methyl)-2-(phenylthio)nicotinamide
英文同义词	N-((4-(4-phenylpiperazin-1-yl)tetrahydro-2H-pyran-4-yl)methyl)-2-(phenylthio)nicotinamide;JNJ-479655;N-[[4-(4-PHENYLPIPERAZIN-1-YL)OXAN-4-YL]METHYL]-2-PHENYLSULFANYLPYRIDINE-3-CARBOXAMIDE;JNJ-47965567 (JNJ47965567);2-(Phenylthio)-N-[[tetrahydro-4-(4-phenyl-1-piperazinyl)-2H-pyran-4-yl]methyl-3-pyridinecarboxamide;3-Pyridinecarboxamide, 2-(phenylthio)-N-[[tetrahydro-4-(4-phenyl-1-piperazinyl)-2H-pyran-4-yl]methyl]-;JNJ-47965567 >=98% (HPLC);JNJ-47965567
CAS号	1428327-31-4
分子式	C28H32N4O2S
分子量	488.64
EINECS号
相关类别
Mol文件	1428327-31-4.mol
结构式

N-[[4-(4-PHENYLPIPERAZIN-1-YL)OXAN-4-YL]METHYL]-2-PHENYLSULFANYLPYRIDINE-3-CARBOXAMIDE 性质

储存条件	2-8°C
溶解度	DMF:30.0(最大浓度 mg/mL);61.39(最大浓度 mM) DMSO:59.62(最大浓度 mg/mL);122.01(最大浓度 mM) DMSO:PBS ( pH 7.2) (1:3):0.25(最大浓度 mg/mL);0.51(最大浓度 mM) 乙醇:12.5(最大浓度 mg/mL);25.58(最大浓度 mM)
形态	粉末
颜色	白色至米色

N-[[4-(4-PHENYLPIPERAZIN-1-YL)OXAN-4-YL]METHYL]-2-PHENYLSULFANYLPYRIDINE-3-CARBOXAMIDE 用途与合成方法

生物活性

JNJ-47965567 是一种中枢通透性、高亲和力、选择性的 P2X7 拮抗剂，对人和大鼠 P2X7 作用的 pKi 值分别为 7.9 和 8.7。JNJ-47965567 可用于探讨中枢 P2X7 在中枢神经系统病理生理模型中的作用。

靶点

pKi: 7.9 (huaman P2X7), 8.7 (rat P2X7)

体外研究

JNJ-47965567 exhibits high affinity for human and rat P2X7 in membrane preparations of 1321N1 cells.
JNJ-47965567 does not block IL-6 and TNF-α release, under identical conditions (LPS and BZ-ATP) used for IL-1β and IL-18 release.
JNJ-47965567 attenuates IL-1β release with pIC ₅₀ s of 6.7 ± 0.07 (human blood), 7.5 ± 0.07 (human monocytes) and 7.1 ± 0.1 (rat microglia), respectively, in native systems.

体内研究

JNJ-47965567 (30-100 mg/kg; s.c.) attenuates IL-1β release induced by Bz-ATP.
JNJ-47965567 (30 mg/kg) attenuates amphetamine-induced hyperactivity and exhibits modest, yet significant efficacy in the rat model of neuropathic pain.

Animal Model:	Male Sprague Dawley rats
Dosage:	30 mg/kg, 100 mg/kg
Administration:	Subcutaneous injection; 30 minutes prior to Bz-ATP infusion
Result:	Significantly attenuated IL-1β release at 100 mg/kg, with no effect at 30 mg/kg dose group.

安全信息

MSDS信息

N-[[4-(4-PHENYLPIPERAZIN-1-YL)OXAN-4-YL]METHYL]-2-PHENYLSULFANYLPYRIDINE-3-CARBOXAMIDE 价格(试剂级)

更新日期	产品编号	产品名称	CAS号	包装	价格
2024/04/30	HY-101418	N-[[4-(4-PHENYLPIPERAZIN-1-YL)OXAN-4-YL]METHYL]-2-PHENYLSULFANYLPYRIDINE-3-CARBOXAMIDE JNJ-47965567	1428327-31-4	10mM * 1mLin DMSO	806元
2024/04/30	HY-101418	N-[[4-(4-PHENYLPIPERAZIN-1-YL)OXAN-4-YL]METHYL]-2-PHENYLSULFANYLPYRIDINE-3-CARBOXAMIDE JNJ-47965567	1428327-31-4	10mg	1200元

N-[[4-(4-PHENYLPIPERAZIN-1-YL)OXAN-4-YL]METHYL]-2-PHENYLSULFANYLPYRIDINE-3-CARBOXAMIDE